Pioneering Advances in Care and Education (PACE)

Prostate Cancer Clinical Trial

— PACE  

Official title:

Development, Validation, and Dissemination of an Integrated Risk Prediction Model and Decision Aid to Discern Aggressive Versus Indolent Prostate Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03397160
• Other study ID #: 14-12951 / UCSF-HDFCC 17553
• Secondary ID: A-17812.5a,b,c,d
• Status: Completed
• Phase: N/A
• Start date: July 19, 2018
• Est. completion date: September 30, 2020

Study information

• Verified date: June 2023
• Source: University of California, San Francisco
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical trial evaluates the use of novel decision support educational materials and services using health coaches. The study includes men newly diagnosed with low-risk prostate cancer. A 160 men will be recruited. Half of the men will receive a call from a health coach before their initial consultation visit with their urologist to review their treatment concerns and questions. The other half will receive usual care provided by the urologist, such as educational materials and services provided by the urologist.

Description:

A critical public health need exists for improved prognostic tools to distinguish aggressive from slow growing prostate cancer at diagnosis, and for better support systems to guide patients in decision-making regarding management options.

Decision support interventions that are tailored to specific clinical conditions are known to have increased patient self-efficacy, knowledge, question-asking, and satisfaction; and decreased decisional conflict, regret, anxiety, and distress.

To reduce the risk of over-treatment, our team has developed individual risk prediction models that we have now integrated into our decision support intervention (DSI).

Delivering such decision support intervention should increase patient knowledge and question-asking by the patient to their doctor.

The decision support intervention can be delivered by telephone and or the Internet.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 119
• Est. completion date: September 30, 2020
• Est. primary completion date: September 30, 2020
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male >=18 years of age and newly diagnosed prostate cancer (PCa) (within 3-months).

• Documentation of a low-risk PCa diagnosis as evidenced by clinical features of the following criteria:

• PSA test at diagnosis <=15 ng/ml

• Localized PCa (cT1/T2,N0,M0)

• Biopsy Gleason grade 2-6 OR (or 3+4 AND <=33% cores are positive for adenocarcinoma)

***A minimum of 10 diagnostic cores taken by a systematic directed approach. Sampling may be obtained by target transrectal ultrasound (TRUS) or MRI imaging.

• No treatment yet

• No previous radiation or simultaneous use of androgen deprivation

• Prior use of 5-alpha reductase inhibitor is allowed if they have been stopped for 6 or more months and biopsy performed when patient was not taking the drug

• English language proficient and ability to provide informed consent

• Managing urologist considers them a candidate for active surveillance

• Written informed consent (and assent when applicable) obtained from subject and ability for subject to comply with the requirements of the study, including the ability to read and speak English.

Exclusion Criteria:

• Participants will be ineligible if they:

1. have pursued any active therapy for prostate cancer will be excluded;

2. are unable to read/speak English; or

3. if their managing urologist does NOT deem them as a candidate for active surveillance.

Related Conditions & MeSH terms

• Decision Support Systems, Clinical
• Prostate Cancer
• Prostatic Neoplasms

Intervention

Behavioral:
• Decision Support Intervention (DSI)
A question list (QL) that includes areas of patient concern are created by the health coach for use by the patient and the urologist at their first consultation visit where they discuss the extent of their cancer and consider treatment options. The coach uses the Prostate Cancer SCOPED model to complete a "Prostate Cancer SCOPED Model Form". The SCOPED model uses concepts such as the situation, choices (treatment), objectives (personal goals and priorities), people (involved in supporting a treatment decision), evaluation and decisions (clarifying which choice is best and next steps).

Locations

Country	Name	City	State
United States	Lancaster Urology	Lancaster	Pennsylvania
United States	Palo Alto Medical Foundation	Palo Alto	California
United States	University of California San Francisco	San Francisco	California
United States	CentraCare Clinic Adult & Pediatric Urology	Sartell	Minnesota

Sponsors (5)

Lead Sponsor	Collaborator
University of California, San Francisco	CentraCare Adult & Pediatric Urology, Lancaster Urology, Palo Alto Medical Foundation, San Francisco Veterans Affairs Medical Center

Country where clinical trial is conducted

United States, 

References & Publications (1)

https://www.frontiersin.org/articles/10.3389/fruro.2023.1127089/full

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Decision Quality Index (DQI) scores	The DQI measures patient Knowledge, Concordance, and Decision process. For each fact about prostate cancer item, a correct response = 1 point. Missing responses=0 points. Total score is calculated for all patients who complete at least half of the items and scaled from 0-100%, with higher scores indicating greater knowledge. Patients rate their goals and concerns on an 11-point importance scale from 0 (not important at all) to 10 (extremely important). These questions + one question about patient's treatment preference can be used to calculate a concordance score. Patients are asked about whether they were offered a choice, how much pros and cons were discussed, and whether the health care provider asked for their preferences. Participants get 1 point for a response of "yes" / "a lot/some.", total points are summed, then divided by total number of items for a decision making process score from 0-100%. Higher scores indicate a more shared decision making process.	12 months
Secondary	Memorial Anxiety Scale for Prostate Cancer (MAX-PC) scores	The MAX-PC is an 18-item questionnaire with a 4-point Likert-type scale asking how frequently certain "comments made by men about prostate cancer" were true of the respondent (Roth et al., 2003). Each item is scored from 0 to 4 with anchors ranging from "Not at all" to "Often." The scale can be scored in its entirety by summing all the items or summary scores can be grouped into Prostate Cancer Anxiety (11 items), Prostate-specific antigen (PSA) Anxiety (3 items), or Fear of Re-occurrence (4 items).	12 months
Secondary	Decision Self-Efficacy (DSE) Scores	The DSE measures self-confidence or belief in one's ability to make informed decisions and participate in shared decision making with health professionals. It is a 11-item instrument with a five-point response scale ranging from 0 (not at all confident) to 4 (very confident).	12 months

External Links

•   UCSF Department of Urology - Study Proposals and Working with Data